2026 BD opportunity scan for Dianthus Therapeutics, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Dendrogenix SA: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Delonix Bioworks Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Daré Bioscience, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Daewoong Pharmaceutical Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rati

2026 BD opportunity scan for D3 Bio (Wuxi) Co. Ltd: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for CSPC Ouyi Pharmaceutical Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rat

2026 BD opportunity scan for CSPC Megalith Biopharmaceutial Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outrea

2026 BD opportunity scan for CSPC Baike (Shandong) Bio-Pharmaceutical Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals

2026 BD opportunity scan for Crystalys Therapeutics: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for CoRegen, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Convalife (Shanghai) Co. Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rational